Author

Jan L. Posma

Observed names: J. L. POSMA, J. L. Posma, J. Posma, J.L. Posma, Jan L Posma, Jan L. posma, Jan Luitsen Posma, POSMA, JL

Observed institutions: University Medical Center Groningen, Deakin University, Erasmus MC, Amsterdam UMC Location University of Amsterdam, Netherlands Heart Institute, Martini Ziekenhuis, University of Amsterdam, Erasmus University Rotterdam

OpenAlex ID: A5077034206

Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans

2002 · Greetje J. de Grooth, Jan Albert Kuivenhoven, et al. · Circulation · 455

PDF

Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease

1993 · Isabelle C. Van Gelder, Harry J.G.M. Crijns, et al. · The American Journal of Cardiology · 269

Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation

2014 · R. G. Tieleman, Y. Plantinga, et al. · EP Europace · 138

PDF

Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure

2017 · Milton Packer, John J.V. McMurray, et al. · JACC Heart Failure · 132

PDF

Effects of Alagebrium, an Advanced Glycation Endproduct Breaker, on Exercise Tolerance and Cardiac Function in Patients with Chronic Heart Failure

2011 · Jasper W.L. Hartog, Suzan Willemsen, et al. · European Journal of Heart Failure · 127

PDF

Fat Embolism and Patent Foramen Ovale

1989 · M.W.N. Nijsten, J.P.M. Hamer, et al. · The Lancet · 93

Increased dispersion of refractoriness in the absence of QT prolongation in patients with mitral valve prolapse and ventricular arrhythmias.

1995 · R. G. Tieleman, H. J. Crijns, et al. · Heart · 71

Effects of Alagebrium, an Advanced Glycation End-Product Breaker, in Patients with Chronic Heart Failure: Study Design and Baseline Characteristics of the BENEFICIAL Trial

2010 · Suzan Willemsen, Jasper W.L. Hartog, et al. · European Journal of Heart Failure · 53

PDF

Assessment of quantitative hypertrophy scores in hypertrophic cardiomyopathy: Magnetic resonance imaging versus echocardiography

1996 · Jan L. Posma, Paul K. Blanksma, et al. · American Heart Journal · 48

Effectiveness and safety of dabigatran versus acenocoumarol in ‘real-world’ patients with atrial fibrillation

2016 · Jennie Korenstra, E. Petra J. Wijtvliet, et al. · EP Europace · 41

PDF

Effects of permanent dual chamber pacing on myocardial perfusion in symptomatic hypertrophic cardiomyopathy.

1996 · J. L. Posma, P. K. Blanksma, et al. · Heart · 38

PDF

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial

2014 · Eliot A. Brinton, Uma Kher, et al. · Journal of clinical lipidology · 28

Favourable outcome in idiopathic ventricular fibrillation with treatment aimed at prevention of high sympathetic tone and suppression of inducible arrhythmias.

1995 · H. J. Crijns, A. C. Wiesfeld, et al. · Heart · 28

PDF

Sustained-release diltiazem versus metoprolol in stable angina pectoris

1989 · J. L. POSMA, R. B. VAN DIJK, et al. · European Heart Journal · 16

Noninvasive measurement of right ventricular systolic pressure by combined color-coded and continuous-wave Doppler ultrasound

1988 · Hans P.M. Hamer, Bert L. Takens, et al. · The American Journal of Cardiology · 15

New diagnostic options in hypertrophic cardiomyopathy

1996 · Jan L. Posma, Ernst E. van der Wall, et al. · American Heart Journal · 14

Redistribution of myocardial perfusion during permanent dual chamber pacing in symptomatic non-obstructive hypertrophic cardiomyopathy: a quantitative positron emission tomography study.

1996 · J. L. Posma, P. K. Blanksma, et al. · Heart · 14

PDF

Acute Intravenous Versus Chronic Oral Drug Effects of Verapamil on Left Ventricular Diastolic Function in Patients with Hypertrophic Cardiomyopathy

1994 · Jan L. Posma, Paul K. Blanksma, et al. · Journal of Cardiovascular Pharmacology · 9

Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT

2024 · Pascal M Burger, Deepak L Bhatt, et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 5

901-103 Effects of Dual Chamber Pacing on Myocardial Ischemia in Hypertrophic Cardiomyopathy Studied with 13-N Ammonia and 18-FDG Positron Emission Tomography

1995 · Jan L. posma, Paul K. Blanksma, et al. · Journal of the American College of Cardiology · 1

PDF

Positron Emission Tomography Characterization of the Myocardium in Hypertrophic Cardiomyopathy

1995 · Paul K. Blanksma, Jan L. Posma, et al. · Developments in cardiovascular medicine · 1

Dispersion of Refractoriness as a Cause of Ventricular Arrhythmias in Patients With Mitral-valve Prolapse

1994 · TIELEMAN, RG, WIESFELD, ACP, et al. · University of Groningen research database (University of Groningen / Centre for Information Technology) · 1

Abstract 16338: Efficacy and Safety of Dabigatran versus Acenocoumarol in “Real World” Patients With Atrial Fibrillation

2014 · Jennie Korenstra, Petra Wijtvliet, et al. · Circulation

VERDICT: acute versus routine serial cardioversion therapy and the role of calcium lowering for maintenance of sinus rhythm after cardioversion of chronic atrial fibrillation.

2000 · A.G. Kloppenburg, J.L. Posma

VERDICT: acute versus routine seriële cardioversie-therapie en de rol van het verlagen van calcium voor handhaving van sinusritme na cardioversie van chronisch boezemfibrilleren.

2000 · A.G. Kloppenburg, J.L. Posma

Works count: 29

Citation count: 1,597

H-index: 15

I10-index: 17